LIVER FIBROSIS IS CHARACTERIZED by the replacement of liver tissue by fibrous scar tissue and the development of regenerative nodules, leading to progressive loss of liver function (22) . The "golden" standard to assess progression of liver fibrosis is a liver biopsy (1, 10) , but it is associated with several complications such as intraperitoneal hemorrhage (ϳ1%), puncture of the gallbladder, pneumothorax (both Ͻ0.5%), and in very rare cases even death (0.01-0.001%) (18, 20) . Because of these limitations, there is an increasing demand for noninvasive serum tests and imaging techniques to assess the stage of liver fibrosis. In this regard, interest is raised in serum N-glycan profiles as potential indicator of liver disease.
The majority of serum proteins are produced by the liver and nearly all of these proteins are N-glycosylated, a noticeable exception being albumin. Recently, a new technological platform, DNA sequencer-assisted-fluorophore-assisted capillary electrophoresis (DSA-FACE) (14) , has been developed to assess glycan structures. This has led to the discovery of a noninvasive test characteristic for end-stage cirrhosis, the GlycoCirrhoTest. This test is defined by the logarithmic proportion of the peak heights of a biantennary, ␣1-6 fucosylated, and bisecting N-acetylglucosamine (GlcNAc) modified sugar (NA2FB, increased in cirrhosis) and a triantennary sugar (NA3, decreased in cirrhosis) in the electropherogram (3) .
NA2FB represents the increase of bisecting GlcNAc-modified glycans in cirrhotic patients, and NA3 represents the decrease of multiantennary glycans in the serum of cirrhotic patients. This is associated with the upregulation of N-acetylglucosaminyltransferase III (GnT-III, responsible for bisecting GlcNAc-modified glycans) and the competitive decrease of N-acetylglucosaminyltransferase V (GnT-V, responsible for multiantennary glycans) in regenerative nodules, and these occur per definition only in the cirrhotic stage.
Undergalactosylation (UGS), the increase of agalacto glycans in serum, is also an important feature in the glycosylation patterns of liver patients. These glycans, which lack one or both galactoses, progressively increase with Metavir stage (2) , and they can be predominantly found on immunoglobulin G (IgG) (21) . UGS of IgG forms the basis of the GlycoFibroTest. Finally, it was shown that the increased abundance of an ␣1-3 fucosylated glycan, NA3Fb, is associated with the development of hepatocellular carcinoma (HCC) in hepatitis B (HBV) patients (15) . Callewaert et al. (3) showed the potential of glycome research in biomarker discovery. Complementary to this study, we wanted to investigate the impact of etiology on N-glycosylation patterns. Therefore, we examined five patient populations of different etiology: cholestatic, HBV, hepatitis C (HCV), alcoholic, and nonalcoholic steatohepatitis (NASH) patients and one control population of healthy volunteers. Importantly, it was observed that patients with an elevation in serum total bilirubin level (Ͼ2 mg/dl) had a significant increase of peak height of glycans modified with ␣1-6 fucose. Therefore, the fucosylation index (FI), defined as the percentage of ␣1-6 fucosylated glycans in the glycome of serum proteins, was significantly elevated in fibrosis/cirrhosis patients with increased levels of total bilirubin. An increase of the FI has especially been linked with HCC patients (6, 17) , and, therefore, we also tested some HCC serum samples with normal (0 -1 mg/dl) and elevated (Ͼ2 mg/dl) total bilirubin serum level. Moreover, patients with a strong elevation of total bilirubin level were excluded in the original studies (3, 21, 15) .
To confirm the results of the human data, we investigated the N-glycosylation patterns of two mouse models of chronic liver disease, common bile duct ligation (CBDL) and subcutaneous injections with carbon tetrachloride (CCl 4 ). In addition, a mouse model for a pure portal hypertension (PHT) without liver damage, partial portal vein ligation (PPVL), was also evaluated.
MATERIALS AND METHODS
Human liver patients. Five patient populations of at least 15 patients each were assembled (Table 1) . Each group had a specific etiology: cholestasis (n ϭ 15), HBV (n ϭ 20), HCV (n ϭ 32), alcoholic (n ϭ 31), and NASH (n ϭ 17). The cholestatic group consisted of 1 patient with progressive familial intrahepatic cholestasis, 9 patients with primary sclerosing cholangitis, and 5 patients with primary biliary cirrhosis. Most of the alcoholic patients kept to a regime of alcohol abstinence at the time of analysis; there was only one active drinker (Ͼ21 alcoholic consumptions/wk). The majority of HBV patients (70%) were on treatment. We also included a control group of 16 healthy volunteers and a HCC group of 16 patients ( Table 2) . The volume of the tumor in a HCC patient was calculated on the basis of the diameter (Ͼ1 cm) of the nodule(s) reported by the radiologist on CT scan. In the case of multiple nodules, the different diameters were counted up. Subsequently, the formula to calculate the volume of a sphere (4/3r
3 ) was used to assess tumor volume. Medical records of these patients were reviewed. Liver tests, Metavir stage if determined by biopsy, other underlying diseases or conditions, and clinical manifestations were assessed. All patients and volunteers signed an informed consent, and the protocol was approved by the ethical committee of the Ghent University Hospital. Serum samples of patients and controls were taken fasted.
The concentration of bile acids in serum was spectrophotometrically determined on a Hitachi 912 analyzer (Diagnostica; Boehringer Mannheim, Ingelheim, Germany) by use of a commercial kit (Trinity Biotech, Co. Wicklow, Ireland). The alanine aminotransferase activity (ALT), aspartate aminotransferase activity (AST), ␥-glutamyl transferase (GGT), alkaline phosphatase (AP), C-reactive protein (CRP), total bilirubin, and total protein were analyzed by routine photometric test on a Hitachi 747 analyzer (Diagnostica, Boehringer Mannheim).
Animal models. Male C57Bl/6 mice (25-30 g) were purchased from Harlan Laboratories (Horst, The Netherlands). The mice were kept under constant temperature and humidity in a 12-h controlled light-dark cycle. The Ethical Committee of experimental animals at the faculty of Medicine and Health Sciences, Ghent University, Belgium, approved the protocols.
The mouse model for a pure PHT without liver damage was induced by PPVL (7). The surgical procedure was performed under sterile conditions. Mice were anesthetized under isoflurane inhalation (Forene; Abbott, Brussels, Belgium). A midline abdominal incision was performed and the portal vein was separated from the surrounding tissue. A ligature (silk cut 5-0) was tied around both portal vein and adjacent 27-gauge blunt-tipped needle. Subsequent removal of the needle yielded a calibrated stenosis of the portal vein. Mice were euthanized at 7 and 14 days after PPVL (n ϭ 8 in each group). The portal venous pressure was measured in PPVL and Sham mice. The portal vein was cannulated through an ileocolic vein with a 24-gauge catheter (Becton Dickinson, Erebodegem-Aalst, Belgium), which was advanced into the portal vein and connected to a highly sensitive pressure transducer (Powerlab, ADInstruments, Spechbach, Germany). The external zero reference point was placed at the midportion of the animal.
The mouse model for a secondary biliary cirrhosis is CBDL (13). The surgical procedure was performed under sterile conditions. Under isoflurane inhalation anesthesia, a midline abdominal incision was made and the common bile duct was isolated. The common bile duct was occluded with a double ligature of a nonresorbable suture (silk cut 5-0). The first ligature was made below the junction of the hepatic ducts and the second was made above the entrance of the pancreatic duct. The common bile duct was sectioned between the two ligatures. Mice were euthanized 1, 3, 4, 5, and 6 wk after CBDL (n ϭ 8 in each group). Sham-operated mice were used as control group for the CBDL and PPVL model (n ϭ 8 in each group).
Finally, the third mouse model was induced by chronic subcutaneous administration of CCl4 (Merck, Darmstadt, Germany) twice weekly (1:1 dissolved in olive oil; 1 ml/kg) (11), and 5% alcohol was added to drinking water. Mice were euthanized after 1, 3, 6, 10, and 16 wk (n ϭ 8 per group). Control mice for CCl 4 received a saline solution (1 ml/kg) subcutaneously (n ϭ 8 in each group). No alcohol was added to the drinking water. The time points at which the mice in the different mouse models were euthanized roughly correspond with the semiquantitative Metavir stage (2) as validated in a previous study (8) .
Blood samples were taken by puncture of the aorta abdominalis. These samples were centrifuged at 2,000 rpm for 10 min. At least 200 l of serum was taken off the clot and the ALT, AST, and total bilirubin were analyzed as described for the human samples. The remaining serum volume was used for the analysis of the N-glycan profiles and to perform two ELISAs for the determination of the serum IgG and serum amyloid A concentration (Immunology Consultants Laboratory, Newburg, OR). The ELISAs were run according to manufacturer's instructions and all analyses were done in duplicate.
Histopathology of the mouse liver was performed by staining with 0.1% picrosirius red. Microscopic evaluation was carried out blinded by two independent investigators (J. Vanhuysse and B. Blomme). Scoring of the liver tissues was done to determine the stage of fibrosis, and this was expressed according to the Metavir score (2) with the emphasis on the fibrosis and not on activity.
Serum protein N-glycome sample processing. The 96-well onmembrane deglycosylation method (14) was used to prepare 8-aminopyrene-1,3,6-trisulfonate (APTS)-labeled N-glycans from 5 l serum. Samples were finally reconstituted in 5 l Milli-Q water and analyzed by DSA-FACE.
To get an idea about the structures of the glycans present in the mouse profiles, exoglycosidase array sequencing was applied. Batches (0.5 l) of APTS-labeled N-glycans were subjected to digestion with different mixtures of exoglycosidases in 5 mM NH4Ac (pH 5). The enzymes used were Arthrobacter ureafaciens sialidase, Streptococcus pneumoniae ␤-1,4-galactosidase, jack bean ␤-N-acetylhexosaminidase, and bovine kidney ␣-fucosidase. After complete digestion (overnight at 37°C), the samples were evaporated to dryness, reconstituted in 10 l water, and analyzed by DSA-FACE.
Data processing. We quantified the heights of 11 peaks that were detectable in all mouse and human samples ( Fig. 1 ) to obtain a numerical description of the profiles and analyzed these data with SPSS 15.0 software (SPSS, Chicago, IL). First, the sum of the peak heights of all the peaks were calculated (total intensity) and then the peak heights were normalized to the total intensity of the measured peaks (expressed as percentage of the total intensity).
All mouse data were analyzed with Mann-Whitney U-test (control vs. treated). The human data were statistically processed as appropriate for the study design (independent sample t-test, single-factor ANOVA, Kruskal-Wallis test, and multiple linear regression). A P value less than 0.05 was considered significant in all analyses.
RESULTS
Alcoholic patients have a significant higher mean value for the GlycoCirrhoTest. The analysis was done on cirrhotic HCV (n ϭ 21) and cirrhotic alcoholic patients (n ϭ 23). The relative percentage of NA2FB was significantly higher in the alcoholic group compared with the HCV group (8.9 Ϯ 2.8 vs. 6.4 Ϯ 2.4%) (P ϭ 0.004; two-tailed t-test). The relative percentage of NA3 was not significantly different between the two groups (P ϭ 0.164; two-tailed t-test), although the mean value in the alcoholic group was lower than in the HCV group (2.5 vs. 3.1%). As a consequence, the mean value of the GlycoCirrhoTest was almost double as high in the alcoholic group compared with the HCV group (0.59 Ϯ 0.33 vs. 0.31 Ϯ 0.26) (P ϭ 0.005; two-tailed t-test). The cirrhotic patients in the other etiologies also had a mean value that was considerably lower than that of The glycan structures of all the peaks in the human profile are known: Peak 1 indicates an agalacto ␣1-6 fucosylated biantennary glycan (NGA2F), peak 2 indicates an agalacto ␣1-6 fucosylated bisecting biantennary glycan (NGA2FB), peaks 3 and 4 indicate a single agalacto ␣1-6 fucosylated biantennary glycan (NG1A2F), peak 5 indicates a bigalacto biantennary glycan (NA2), peak 6 indicates a bigalacto ␣1-6 fucosylated biantennary glycan (NA2F), peak 7 indicates a bigalacto ␣1-6 fucosylated bisecting biantennary glycan (NA2FB), peak 8 indicates a triantennary glycan (NA3), peak 9 indicates a ␣1-3 fucosylated triantennary glycan (NA3Fb), peak 10 indicates a ␣1-6 fucosylated triantennary glycan (NA3Fc), and peak 11 indicates a tetra-antennary glycan (NA4). The symbols used in the structural formulas are as follows: open circle, ␤-linked galactose; square, ␤-linked N-acetylglucosamine; shaded circle, ␣/␤-linked mannose; triangle, ␣-1,3/6-linked fucose. The structures of the peaks in the mouse profile were obtained after exoglycosidase digests. The 3 glycans indicated in the murine profile were clearly deduced from the exoglycosidase digests (data not shown).
alcoholic patients: cholestatic 0.26 Ϯ 0.2, n ϭ 4, and HBV 0.3 Ϯ 0.39, n ϭ 9. These latter observations were still substantially higher compared with the control group (Ϫ0.03 Ϯ 0.15) (Fig. 2) . The value for NASH patients (0.5 Ϯ 0.57, n ϭ 4) was also quite high. Our data set, in all etiologies together, had an area under the receiver operating characteristic curve (AUROC) of 0.81 for the discrimination between F0 -F3 and F4, which was similar to the original study (3) . More informative was the AUROC in the individual etiologies: cholestatic (0.77), HBV (0.72), HCV (0.68), alcoholic (0.96), and NASH (0.83). Finally, we found significant correlations between scores of the GlycoCirrhoTest and various markers of chronic liver disease: GGT, AST, total bilirubin, AP, and bile acids (P Ͻ 0.001; Spearman rank test) and ALT (P ϭ 0.018; Spearman rank test). This was expected because the GlycoCirrhoTest only displays an increase in score in the cirrhotic stage as these parameters were also seen to be elevated at this stage. In contrast, there was no correlation between scores of the GlycoCirrhoTest and viral load in HBV and HCV patients (P ϭ 0.347; Spearman rank test).
No significantly different quantitative alteration in undergalactosylation score between all etiologies. UGS score was defined as {[2ϫ(peak1ϩ2)] ϩ peak 3 ϩ peak 4 }/{[2ϫ(peak1 ϩ peak2 ϩ peak3 ϩ peak4 ϩ peak5 ϩ peak6 ϩ peak7)] ϩ [3ϫ(peak8 ϩ peak9 ϩ peak10)] ϩ (4ϫpeak11)} (expressed in %) (20) .
In the noncirrhotic group (F1-F3), there was no significant difference in UGS score between the etiologies as determined by pairwise comparisons using Scheffé's tests (single-factor ANOVA). The HCV and alcoholic liver disease group showed the highest mean level of UGS score (0.24 and 0.23, respectively), followed by HBV (0.2), cholestatic liver disease, (0.18), and NASH (0.16) (P ϭ 0.322).
The classification according to Metavir stage was possible for the HCV-population (Table 1) . We were able to reproduce the linear increase of UGS score in increasing Metavir stage: F1 0.15, F2 0.25, F3 0.29, and F4 0.32.
In cirrhotic patients, again no significant difference in UGS score between the etiologies was seen (P ϭ 0.054, KruskalWallis H-test). Mean UGS score was highest in cirrhotic NASH patients (0.35), followed by alcoholic (0.34) and HCV (0.32) patients. Cholestatic (0.23) and HBV (0.17) patients had a clearly lower, although not significant, mean level of UGS score.
Fucosylation index is significantly increased in fibrosis/ cirrhosis and HCC patients with an elevation of total bilirubin level. It was observed that the FI of liver patients with an elevation in total bilirubin level (70%) was significantly higher than the FI of liver patients with normal total bilirubin levels (52.9%) (P Ͻ 0.001; two-tailed t-test). The increase in ␣1-6 fucosylation was clearly not linked to etiology (single-factor ANOVA, P ϭ 0.254), only to an elevation in total bilirubin level. The FI was comparable in the progression of F1 to F3 in HCV patients (0.5, 0.58, and 0.52, respectively), but it was clearly elevated in the cirrhotic stage (0.7). Patients with the syndrome of Gilbert had a normal FI. The degree of ␣1-3 fucose did not differ significantly between patients with normal and elevated bilirubin levels (P ϭ 0.687; two-tailed t-test).
We also tested other markers of liver damage (AST, ALT, GGT, AP, CRP, and total protein) to investigate whether these did not confound our results. Only AST and AP were also significantly elevated in the group with increased FI (P ϭ 0.001 and P ϭ 0.034, respectively; two-tailed t-test). Subsequently, we tested eight HCC patients with an elevation in total bilirubin level and eight HCC patients with normal total bilirubin level. Again, the FI in the HCC group with elevated total bilirubin concentrations was significantly higher (70.8 vs. 48.7%, P Ͻ 0.001; two-tailed t-test). Both populations did not differ in ␣-fetoprotein level (P ϭ 0.35; two-tailed t-test) but AST was significantly increased in the HCC group with increased FI (P Ͻ 0.001; two-tailed t-test) in agreement with the results in the fibrosis/cirrhosis group. There was no significant difference in the other markers (ALT, GGT, AP, CRP, and total protein). Again, the level of ␣1,3-fucose did not differ significantly between HCC patients with normal and elevated bilirubin levels (P ϭ 0.585; two-tailed t-test).
We also analyzed the correlation between the scores of the GlycoHCCTest and tumor volume in HCC patients. There was a clear trend observed between the two variables, but significance was not reached (P ϭ 0.054; Spearman rank test). Only one HCC patient showed metastasis and this did not influence the score.
Serum bile acid concentration. Serum bile acid concentration was determined in every fibrosis/cirrhosis and HCC patient. Inconsistent data (low total bilirubin-high FI and vice versa) showed consistency in the bile acid data. Cholestatic patients had a mean serum bile acid concentration of 49.5 mol/l (Ϯ 83.4), HBV patients had a mean value of 16.2 mol/l (Ϯ 26.1), HCV patients had a mean value of 38.6 mol/l (Ϯ 53.2), alcoholic patients had a mean value of 50.2 mol/l (Ϯ 56), NASH patients had a mean value of 67.2 mol/l (Ϯ 85.4) and HCC patients had a mean value of 51.5 mol/l (Ϯ 73).
Only markers for cholestasis correlated significantly with the FI in a multivariate analysis. The total bilirubin and bile acid data were first logarithmically transformed. The correlation between the FI and the discontinuous variables HCC, cirrhosis (cirrhotic and noncirrhotic), and etiology was determined with a two-tailed Spearman test and a single-factor ANOVA. The correlation with the continuous variables total bilirubin, serum bile acid concentration, AST, and AP was determined with a simple linear regression analysis. The variables AST, total bilirubin, serum bile acid concentration, and cirrhosis correlated significantly with the FI (P Ͻ 0.001). Scatter dots of the correlation between the (logarithmically transformed) total bilirubin and serum bile acid concentration are seen in Fig. 3 .
Subsequently, a multiple linear regression analysis was performed with FI as dependent factor and bilirubin level, serum bile acid concentration, AST, AP, HCC, etiology, and cirrhosis as covariants in the linear model. The (logarithmically transformed) total bilirubin level, (logarithmically transformed) bile acid concentration, and AP correlated significantly with the FI (P Ͻ 0.001, P ϭ 0.001, and P ϭ 0.029, respectively) in the linear model. 
Laboratory tests and histological analysis of mouse models of chronic liver disease. Test samples (4 in the PPVL and
Sham groups) confirmed earlier reports that there were no changes in AST, ALT, and bilirubin after PPVL induction (6) . One week after PPVL induction, the portal venous pressure (PVP) was at a mean of 8.3 mmHg (Ϯ 1.9), and 2 wk after PPVL induction mean PVP rose further to 10.7 mmHg (Ϯ 4). This was significantly higher than sham-operated mice that had a mean PVP of 4.3 mmHg (Ϯ 0.8) (P Ͻ 0.001) 1 wk after induction and at 2 wk a PVP of 5 mmHg (Ϯ 1.7) (P ϭ 0.004). Histological examination revealed no significant fibrosis development in PPVL mice at 1 and 2 wk after induction. They were predominantly scored F0.
After 3 wk of CCl 4 administration, the Sirius red stain demonstrated fibrotic changes in the centrilobular area. After 6 wk the liver architecture demonstrated a reversed lobulation due to development of centrocentral fibrotic linkages, and after 10 wk the reversed lobulation was accentuated with the development of centroportal thin fibrotic septa apart from the centrocentral fibrotic linkages. Finally, after 16 wk, all mice had homogeneous characteristics of cirrhosis. For laboratory tests, see Table 3 .
Enlargement of the portal tracts accompanied by dilatation of bile canaliculi and proliferation of the smaller bile ducts appeared as soon as 1 wk after CBDL. After 3 wk, the periportal alterations were accompanied by fibrotic changes to be described as F2 and evolving into F3 after 5 wk of CBDL. After 6 wk, the majority of mice (62.5%) developed cirrhosis with nodular changes in the liver parenchyma. For laboratory tests see Table 3 . Typical cirrhotic images of CBDL and CCl 4 mice are seen in Fig. 4 .
N-glycosylation patterns in mouse models of chronic liver disease. The overall picture of the glycosylation pattern of a PPVL mouse was that of a control sample. One week after PPVL induction, peak 5/NA2 was significantly decreased (P ϭ 0.003) and peak 6 was significantly increased (P ϭ 0.006) compared with sham mice. Two weeks after induction, when PVP is at its maximum (7), only one peak was significantly altered: peak 9 was significantly increased (P ϭ 0.004) compared with Sham mice (Table 4) . However, no systematic changes were observed.
In CCl 4 mice, a significant increase in peaks 9 and 11 in the glycosylation pattern was observed starting from the first week of CCl 4 treatment. Peak 10 also started to increase significantly in abundance from 6 wk on. After 3 wk of CCl 4 , peak 5/NA2 decreased significantly in abundance and at later time points, its two adjacent peaks (peaks 3 and 4) also decreased significantly in abundance (Fig. 5) (for P values, see Table 4 ). CBDL mice were characterized by the significantly increased abundance of peaks 1, 6, and 7 (Table 4 , Fig. 5 ) in the glycosylation pattern. Peak 1/NGA2F increased significantly already in the first week after CBDL and peaks 6 and 7/NA2F after 3 wk CBDL. Fucosidase digest revealed that these are all fucosylated glycans. CBDL mice also exclusively had a significant lowered abundance of peak 8 and, in common with CCl 4 , a decrease in abundance of peaks 4 and 5/NA2. CBDL mice also showed a significantly elevated peak height of peaks 9, 10, and 11 in agreement with CCl 4 mice. Peak 11 was significantly increased in abundance from an early stage on, but peaks 9 and 10 only in the cirrhotic stage (for P values, see Table 4 ).
As a consequence of the increase of fucosylated glycans in CBDL mice, the FI was an excellent marker to distinguish CCl 4 and CBDL mice. This index barely rose above 20% in CCl 4 and control mice, whereas it reaches 30 to 40% in CBDL mice (P Ͻ 0.001 in F2, F3, and F4 stages) (Fig. 6) . We also analyzed one pure bile mouse sample, and the FI was comparable to a serum sample of a CBDL mouse (42%).
IgG and SAA concentration in mouse models of chronic liver disease. Six mice were evaluated at every time point in the CCl 4 and CBDL group and two mice at every time point in the control mice. Both fibrotic mouse models showed a doubling of the IgG concentration in the progression of fibrosis to cirrhosis (from ϳ0.5 mg/ml to ϳ1.3 mg/ml). Apart from an early strong increase in serum amyloid A (SAA) concentration (a mean of 700 g/ml after 3 wk, in the CCl 4 model and a mean of 320 g/ml after 1 wk in the CBDL model) no significant difference in SAA concentration between the CCl 4 , CBDL, and control mice could be observed (baseline value was ϳ50 g/ml).
DISCUSSION
Alteration of total serum N-glycans is indicative for chronic necroinflammatory diseases, and especially in liver diseases it shows great potential as biomarker (3, 15, 21) . Our group has made important contributions to this research with a follow-up tool for fibrosis (21) and noninvasive tests for cirrhosis and HCC (3, 15) . Alcoholic patients were shown to have a mean value for the GlycoCirrhoTest that was considerably higher than in other liver patients. This could be due to the micronodular fibrotic nature of the liver of alcoholic patients. More nodules correspond to more elevated GnT-III induction in the cirrhotic liver (3). The mean value of NASH patients was also quite high, but this was due to one outliner in a limited number of samples. Nevertheless, the mean value of the cirrhotic patients in all etiologies was significantly and considerably higher than the mean value of the control group. Chen et al. (4) stated that NASH patients had no change in expression of GnT-III and GnT-V and these patients could therefore not be diagnosed with the GlycoCirrhoTest. However, we found that three of our four cirrhotic NASH patients had a high value for the GlycoCirrhoTest, well over the cutoff value for cirrhosis, which implies strong upregulation of GnT-III and concomitant downregulation of GnT-V (Fig. 2) .
UGS of IgG in the progression of fibrosis is the feature on which the GlycoFibrotest is mainly based. This article shows that there was no significantly different quantitative alteration in undergalactosylation in the cirrhotic as well as in the noncirrhotic population across all etiologies (Fig. 2) . Remarkable was the strong increase of UGS score in cirrhotic NASH patients compared with the noncirrhotic group. The overall higher mean value of UGS in the cirrhotic stage (with the exception of HBV) can be attributed to the linear increase of the mean UGS state of IgG that reaches a maximum in end-stage liver disease (21) as exampled in HCV patients.
An important finding was that an elevation of total bilirubin is strongly associated with a consequent increase of the FI. In a multiple regression model, a significant correlation was found with the (logarithmically transformed) bile acid concentration and AP. These biochemical variables are markers for liver damage, but specifically for cholestasis.
Increase in fucosylation has especially been linked with HCC and an upregulation of fucosyltransferases in hepatoma tissue was suggested to be the driving force after this increased fucosylation of serum proteins (5, 18 ). An alternative hypothesis in non-HCC cholestatic patients reasons that ␣1-6 fucosylation of N-linked glycans within polarized hepatocytes directs glycoproteins to the basolateral surface and into bile. As a consequence, ␣1-6 fucosylated glycoforms are normally rare in the blood and are enriched in the bile. Thus, if liver cells become depolarized, the ␣1-6 fucosylated glycoforms rise in abundance in the blood (16) . The data collected in this study strongly favor the latter hypothesis. Moreover, the presence of high concentrations of bile acids in the serum samples with high FI is a strong confirmation of our data.
In the setting of cholestasis, the basolateral path to the bile ducts is blocked. Therefore, we hypothesize that there is an accumulation of ␣1-6 fucosylated glycoproteins in the hepatocyte. The only exit for these glycoproteins is apically to the space of Disse and eventually to the systemic circulation. In conclusion, ␣1-6 fucosylation seems to be not a HCC marker, but a marker for hyperbilirubinemia.
Our group has previously shown that ␣1-3 fucose significantly increases in HCC patients (15) . However, we could not reproduce this upregulation of ␣1-3 fucose, possibly because we used a mixed HCC population of different etiologies in contrast to the original study that was uniquely performed in HBV patients (15) . The ␣1-3 fucose did not differ significantly between patients with normal and elevated bilirubin level, in both fibrosis/cirrhosis and HCC patients.
The mouse models allowed us to investigate some variables independently from each other. The influence of PHT was investigated with PPVL mice. No biologically relevant changes in N-glycosylation were observed in the PPVL mice, indicating that PHT does not contribute to the alteration of N-glycosylation in liver diseases.
The effect of elevated total bilirubin levels on N-glycosylation can be studied with CBDL mice. In analogy with liver patients that had a strong increase in total bilirubin, CBDL mice had a strong increased abundance of all ␣1-6 fucosylated glycans. An additional advantage of mouse models is the easy follow-up of histology and there is also less bias in the histological analysis of the mouse liver. In this respect, we were able to observe that the increase of ␣1-6 fucosylation is an early event in the cholestatic development (Table 3) .
CCl 4 mice did not show an increase in total bilirubin level and these mice therefore did not have an increased FI. These mice develop a micronodular fibrosis/cirrhosis with characteristics of an alcoholic cirrhosis, and it is also considered as a model with an important amount of inflammation. However, inflammation did not have an influence on the N-glycosylation patterns in these mouse models. Apart from an early peak in SAA concentration, no significant difference was observed and there was no such correlation with the N-glycosylation patterns of the mouse models. The hallmarks of CCl 4 mice are an increase of peaks 9, 10, and 11, probably all multiantennary glycans. Again, this occurred very early in the fibrotic development and was not unique to CCl 4 mice because also CBDL mice had a significant increased abundance of these three glycans, albeit later in the fibrotic development. Other common changes with CBDL were a significant decrease in abundance of peak 5/NA2 and its adjacent peak 4.
Some N-glycosylation aspects of human liver patients are difficult to study in mouse models. Even if UGS would be present in mouse models, it would be much less pronounced than in humans because the IgG concentration in serum is inherently low at 0.5 to 1.5 mg/dl. Additionally, in mice, glycan modifications that do not exist in humans, especially ␣-galactosylation, are present (12) . Therefore, the baseline N-glycosylation pattern of a control C57Bl/6 mouse will be different than the baseline N-glycosylation pattern of a healthy human control (Fig. 1) . Moreover, our study strongly suggests that the spectrum of N-glycosylation alterations in liver disease is different between mice and humans. In summary, caution is offered when extrapolating mouse data.
In conclusion, we have shown that the GlycoFibroTest and GlycoCirrhoTest can be used in all etiologies as universal noninvasive tests. An important finding was that liver patients with elevated total bilirubin levels have a significant increase of glycans modified with ␣1-6 fucose. When studying fucosylation, a distinction has to be made between an increase of ␣1-6 fucose, which is a marker for hyperbilirubinemia, and an increase of ␣1-3 fucose, which is a marker for HCC, the latter most likely exclusively in HBV patients. Future studies on biomarker discovery based on N-glycosylation will have to take into account that an increase of total bilirubin is attended with an increase of ␣1-6 fucosylation in serum.
